QY201 Tablets（20mg）

DRUG2 trials

Sponsors

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Conditions

Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)Adult Subjects With Non-Segmental Vitiligo

Phase 2

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

CompletedNCT07712536

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

Start: 2025-06-04End: 2025-12-19Updated: 2026-07-17

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

RecruitingNCT07712523

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Adult Subjects With Non-Segmental Vitiligo

Start: 2025-11-05End: 2026-12-31Target: 200Updated: 2026-07-17